Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Rami Moucari"'
Autor:
Michèle Pouteau, Corinne Castelnau, Patrick Marcellin, N. Giuily, Nathalie Boyer, Rami Moucari, Sarah Maylin, Tarik Asselah, Michelle Martinot-Peignoux, M. Lapalus
Publikováno v:
Journal of Viral Hepatitis. 23:905-911
Quantitative hepatitis B core-related antigen (qHBcrAg) has been proposed as an additional marker to quantitative HBsAg (qHBsAg), for management of chronic hepatitis B. Evaluate baseline combination of qHBsAg and qHBcrAg for identification of patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc92e1f546d55003284fa49ce86763d4
https://doi.org/10.1111/jvh.12565
https://doi.org/10.1111/jvh.12565
Autor:
S. De Muynck, Olivier Lada, E. Estrabaud, Cédric Laouénan, M. Lapalus, Pierre Bedossa, Michelle Martinot-Peignoux, Nathalie Boyer, Patrick Marcellin, Michel Vidaud, Q. Zhang, Tarik Asselah, Ivan Bièche, Rami Moucari
Publikováno v:
Journal of Viral Hepatitis. 21:525-532
The impact of IFNL3 (IL28B) polymorphism on response to interferon (IFN) treatment in patients infected with hepatitis B virus (HBV) is controversial. We aimed to investigate whether IFNL3 polymorphism (rs12979860) influences the long-term response o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49a06f0927a1dd552a9f09c44a03e5b6
https://doi.org/10.1111/jvh.12177
https://doi.org/10.1111/jvh.12177
Publikováno v:
Current Hepatitis Reports. 11:75-81
Pegylated Interferon alfa (PEG-IFN) is the only licensed agent that allows a sustained virologic response in a subset group of patients with chronic hepatitis B, both e antigen (HBeAg)-positive and negative, after a finite course of therapy. Despite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8ff27316a1e80a82f63581a0fdba078
https://doi.org/10.1007/s11901-012-0126-6
https://doi.org/10.1007/s11901-012-0126-6
Autor:
Aurélie Plessier, Michel Vidaud, Dominique Valla, Marie-Hélène Denninger, Richard Moreau, Rami Moucari, Didier Lebrec, Sylvie Escolano, Pierre-Emmanuel Rautou, Raphael Itzykson, Annie Bezeaud, Ludivine Douarin
Publikováno v:
Journal of Hepatology. 54:56-63
Background & Aims Anticoagulation therapy is recommended for patients with Budd–Chiari syndrome (BCS). This study aimed to assess the incidence, severity, and risk factors of major bleeding in patients with Budd–Chiari syndrome (BCS) receiving an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27cc75e5d2493ffcfa868ed523d1cd50
https://doi.org/10.1016/j.jhep.2010.06.019
https://doi.org/10.1016/j.jhep.2010.06.019
Autor:
Rami Moucari, Patrick Marcellin
Publikováno v:
Liver International. 31:122-128
HBsAg is a very important clinical test that might not only indicate active hepatitis B virus (HBV) infection but might also be used to predict clinical and treatment outcome. Clearance of HBsAg in patients with chronic HBV infection is associated wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::719ab5d890f991845422e2207d14896c
https://doi.org/10.1111/j.1478-3231.2010.02390.x
https://doi.org/10.1111/j.1478-3231.2010.02390.x
Autor:
Rami Moucari, Patrick Marcellin
Publikováno v:
Gastroentérologie Clinique et Biologique. 34:S119-S125
Chronic hepatitis B is a major cause of liver disease worldwide, ranking as the first cause of cirrhosis and hepatocellular carcinoma. Hepatitis B surface antigen (HBsAg) is usually used as a qualitative marker for the diagnosis of hepatitis B virus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60e310b77d568160202af1374cce6216
https://doi.org/10.1016/s0399-8320(10)70031-2
https://doi.org/10.1016/s0399-8320(10)70031-2
Autor:
Marcel Nkuize, Michel Buset, Rami Moucari, Marijke Reynders, Patrick Marcellin, Thomas Sersté, Françoise Vertongen, Jean-Pierre Mulkay, Robert Scheen, Marc Van Gossum
Publikováno v:
Liver International. 30:1131-1136
Background & aim: Patients with hepatitis C virus (HCV) infection, especially those with genotypes 1 and 4, have an increased risk of developing metabolic disorders. The aim of this study was to evaluate the associations among metabolic disorders, et
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a3cdf1aaad76b3c12ee30e815f7577b
https://doi.org/10.1111/j.1478-3231.2010.02291.x
https://doi.org/10.1111/j.1478-3231.2010.02291.x
Autor:
Marie-Pierre Ripault, Corinne Castelnau, Nathalie Boyer, Dominique Valla, Michel Vidaud, Rami Moucari, Patrick Marcellin, Agnes Dauvergne, Marie Hélène Nicolas–Chanoine, Vincent Mackiewicz
Publikováno v:
Journal of Viral Hepatitis. 18:580-586
To assess the impact of sequential therapy with adefovir dipivoxil (ADV) and pegylated interferon alfa-2a (PEG-IFN) on virological (serum HBV-DNA) and serological (serum HBsAg) response in 20 consecutive HBeAg-negative patients. Patients received ADV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5140e38d46ae1dc84eb4eaa103775312
https://doi.org/10.1111/j.1365-2893.2010.01332.x
https://doi.org/10.1111/j.1365-2893.2010.01332.x
Autor:
N. Giuily, Nathalie Boyer, C. Figueiredo-Mendes, Ana-Carolina Cardoso, Marie-Pierre Ripault, Patrick Marcellin, Dominique Valla, Sarah Maylin, Tarik Asselah, Michelle Martinot-Peignoux, Rami Moucari, Pierre Bedossa, Corinne Castelnau, Roberto J. Carvalho-Filho
Publikováno v:
Journal of Hepatology. 52:652-657
Hepatocellular carcinoma (HCC) currently represents the major cause of liver-related death in patients with hepatitis C virus (HCV)-related cirrhosis. We assessed the influence of combination therapy on the risk of HCC, liver-related complications (a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::010da2349a1dbec6cb69a49822c3c079
https://doi.org/10.1016/j.jhep.2009.12.028
https://doi.org/10.1016/j.jhep.2009.12.028
Autor:
Geoffrey Dusheiko, Nizar N. Zein, Adrián Gadano, Jean-Michel Pawlotsky, Rami Moucari, Samir Haffar, E. Jenny Heathcote, Patrick Marcellin, Nabil Antaki, Antonio Craxì, Schalk Van der Merwe, Sanaa M. Kamal, Ching-Lung Lai
Publikováno v:
Liver International. 30:342-355
Hepatitis C virus (HCV) genotypes 4, 5 and 6 represent20% of all HCV cases worldwide. HCV-4 is mainly seen in Egypt, where it represents 90% of all HCV cases. Antischistosomal therapy was the main cause of contamination there, followed by procedures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5f7933f0671c248cc31b02be3be46a4
https://doi.org/10.1111/j.1478-3231.2009.02188.x
https://doi.org/10.1111/j.1478-3231.2009.02188.x